Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System

Published:2021-12-16 Issue: Volume: Page:
ISSN:0023-852X
Container-title:The Laryngoscope
language:en
Short-container-title:The Laryngoscope

Author:

Swisher Austin R.¹^ORCID,Kshirsagar Rijul S.²^ORCID,Adappa Nithin D.²,Liang Jonathan³

Affiliation:

1. University of California Riverside School of Medicine Riverside California U.S.A.

2. Department of Otorhinolaryngology‐Head and Neck Surgery University of Pennsylvania Philadelphia Pennsylvania U.S.A.

3. Department of Otolaryngology‐Head and Neck Surgery Kaiser Permanente Oakland California U.S.A.

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lary.29992

Reference45 articles.

1. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps

2. Dupilumab: Basic aspects and applications to allergic diseases

3. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

4. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

5. Subclassification of chronic rhinosinusitis

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The diagnosis and treatment of chronic rhinosinusitis;Deutsches Ärzteblatt international;2024-09-20

2. A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System;Otology & Neurotology;2024-09

3. Biologic Therapies across Nasal Polyp Subtypes;Journal of Personalized Medicine;2024-04-19

4. Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps;The Laryngoscope;2024-02-05

5. Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment;The Laryngoscope;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3